Investor Relations

Press Releases

Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study

Read More

Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer

Read More

Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

Read More

Advaxis's Lm-LLO Immunotherapy Data to be Presented in Three Posters at the Society for Immunotherapy of Cancer 29th Annual Meeting

Read More

Advaxis Appoints World Renowned Oncologist and Research Scientist, Dr. Samir N. Khleif, to Its Board of Directors

Read More

Advaxis's Chief Scientific Officer, Dr. Robert Petit, Leads Panel Discussion on Combination Immunotherapies

Read More

Advaxis's Cancer Immunotherapy Featured on Fox News

Read More

Advaxis Provides a Clinical Development Update for Its Immunotherapy, ADXS-HPV, for the Treatment of Cervical Cancer

Read More

Advaxis to Present at Upcoming Investor Conferences

Read More

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

Read More